<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="311">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157100</url>
  </required_header>
  <id_info>
    <org_study_id>1002</org_study_id>
    <nct_id>NCT05157100</nct_id>
  </id_info>
  <brief_title>Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia</brief_title>
  <official_title>Prospective, Open-label Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Orthopedic Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Orthopedic Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF CERVICAL DYSTONIA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROSPECTIVE, OPEN-LABEL CLINICAL STUDY OF INGREZZA (VALBENAZINE) FOR THE TREATMENT OF&#xD;
      CERVICAL DYSTONIA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Experimental</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in incidence of pain/spasm</measure>
    <time_frame>16 weeks</time_frame>
    <description>Change in incidence rate of pain/spasm as measured by frequency and intensity in subjects prior to and during use of valbenazine as measured by TWSTRS and IMU.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>Ingrezza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Ingrezza orally once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingrezza Pill</intervention_name>
    <description>Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.</description>
    <arm_group_label>Ingrezza</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Male or female patients between 18 and 85 years of age (inclusive) 2. A clinical&#xD;
             diagnosis of cervical dystonia (ie, spasmodic torticollis) by investigator for at&#xD;
             least six months 3. Moderate to severe head tremor and/or dystonic posturing as judged&#xD;
             by the investigator 4. Stable Botulinum Toxin (Botox, Dysport, Xeomin, or Myobloc)&#xD;
             therapy dosage for at least 3 months prior to baseline visit&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Tardive dyskinesia&#xD;
&#xD;
          2. Predominant anterocollis&#xD;
&#xD;
          3. Concomitant use of strong CYP3A4 inhibitors (i.e. itraconazole, ketoconazole,&#xD;
             clarithromycin), digoxin, strong CYP2D6 inhibitors (i.e.paroxetine, fluoxetine,&#xD;
             quinidine), monoamine oxidase inhibitors (i.e.&#xD;
&#xD;
             isocarboxazid, phenelzine, selegiline)&#xD;
&#xD;
          4. Myotomy or denervation surgery in the affected muscles (eg, peripheral denervation&#xD;
             and/or spinal cord stimulation)&#xD;
&#xD;
          5. Diagnosis of Myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,&#xD;
             or any other significant neuromuscular disease which might interfere with the trial&#xD;
&#xD;
          6. Moderate to severe hepatic impartment as determined by a Child-Hugh Score â‰¥7&#xD;
&#xD;
          7. Marked limitation on passive range of motion that suggests contractures or other&#xD;
             structural abnormality, eg, cervical contractures or cervical spine syndrome&#xD;
&#xD;
          8. Any conditions that may increase the risk associated with study participation or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             Investigator, would make the patient inappropriate for entry into this study&#xD;
&#xD;
          9. Participation in another interventional study during participation in this study&#xD;
&#xD;
         10. Pregnant or lactating females, or females of child-bearing potential not willing to&#xD;
             use an acceptable method of contraception&#xD;
&#xD;
         11. History of hypersensitivity to valbenazine or any components of INGREZZA.&#xD;
&#xD;
         12. Is suicidal at screening as defined by below:&#xD;
&#xD;
               1. According to the C-SSRS, he or she must not be actively suicidal at Visit 1&#xD;
                  (Screening) or Visit 2 (Baseline) (including, an answer of &quot;yes&quot; to C-SSRS&#xD;
                  questions 4 or 5 [current or over the last 6 months]) and must not have attempted&#xD;
                  suicide in the 1 year prior to Visit 1 (Screening); OR&#xD;
&#xD;
               2. The subject is actively suicidal in the Investigator's judgment&#xD;
&#xD;
                  -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Taylor, DO, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>principle investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Orthopedic foundation</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 6, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT05157100/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

